Navigation Links
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Date:10/21/2009

TUSTIN, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer. Preliminary data at the end of the six planned treatment cycles in the Phase II study showed that 28 of 46, or 61%, of all patients enrolled in the trial achieved an objective tumor response according to RECIST criteria. This data compares favorably with data from a published study showing an objective tumor response rate of 41% in a similar patient population receiving the same dosing regimen of docetaxel administered as a single agent.

Joseph Shan, vice president of clinical and regulatory affairs at Peregrine commented, "We are very encouraged by the initial results reported today for the full 46 patients enrolled in the bavituximab plus docetaxel Phase II trial. The tumor response data reported in this study exceeded the tumor response data for docetaxel alone that was used as the benchmark for the design of this study. With these positive initial data in hand, we and our expert advisors believe that this combination regimen warrants further clinical evaluation, and we are now assessing possible trial designs for future studies."

The primary objective of the multi-center, open-label Phase Il study is to assess the overall response rate to bavituximab and docetaxel. In this trial's Simon two-stage design, 15 patients were initially enrolled in the study followed by an additional 31 patients after the pre-specified primary efficacy endpoint for expanding the study was met, bringing the total to 46 patients. Initial data from the first set of 15 patients in the study was reported in an oral presentation at the 2009 ASCO Annual Meeting. Recent analysis showed the median progression-free-survival (PFS) of patients enrolled in the initial 15-patient cohort of the study was 7.4 mo
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
2. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
3. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
5. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
6. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
7. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
8. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
9. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- Robert M. Bernstein, M.D., ... procedures and founder of Bernstein Medical – Center ... Doctors, issue of New York Magazine for the ... ) Dr. Bernstein earned his ... reputation as world-renowned hair restoration physician, through a ...
(Date:6/19/2013)... , June 19, 2013 Amgen is pleased ... United States , Canada and ... recipients of the Amgen Award for Science Teaching Excellence (AASTE). ... at the kindergarten through 12th grade level who have an ... education. With a long-standing commitment to science education, ...
(Date:6/19/2013)... , June 19, 2013 A decade-long JDRF-funded ... Helmholtz Zentrum München, Germany , is ... and the risk of developing type 1 diabetes (T1D), ... for the disease. The study, "Seroconversion to Multiple Islet ... was published today in The Journal of the ...
Breaking Medicine Technology:Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3Amgen Award For Science Teaching Excellence Honors Outstanding Teachers 2Amgen Award For Science Teaching Excellence Honors Outstanding Teachers 3New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 2New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 3
... N.C., April 13, 2011 iAdvantage Software, ... solutions for managing Life Science Research and Development ... (ABC), a Contract Research Organization, headquartered in ... hosted solution to support its Ecotoxicology and other ...
... Healthcare announced interim results of a recently completed randomized ... the clinical  management and diagnosis of adult patients who ... results, presented at the 2011 American Academy of Neurology ... of DaTscan as an adjunct diagnostic tool for use ...
Cached Medicine Technology:Analytical Bio-Chemistry (ABC) Laboratories Implements eStudy™ Hosted Platform to Support its Ecotoxicology and Other Service Offerings 2Analytical Bio-Chemistry (ABC) Laboratories Implements eStudy™ Hosted Platform to Support its Ecotoxicology and Other Service Offerings 3GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 2GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 3GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 4GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 5GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 6
(Date:6/19/2013)... along with the Japanese government and the Bill ... bolster Japan,s contribution to global health through the ... a press conference held as a side event ... Development (TICAD V). , Representatives from each of ... Labour and Welfare, the Ministry of Foreign Affairs, ...
(Date:6/19/2013)... Louisiana State University have developed a method for identifying ... on understanding the genetic interaction between single nucleotide polymorphisms ... cancer,s aggressiveness to avoid unnecessary radical treatment. , ... PLOS ONE in April. , According to the ... cancers and 9 percent of cancer deaths. It is ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Brightree LLC ... business management software solutions for the post-acute care industry, has ... - on the Healthcare Informatics 100 (HCI 100) ... companies in the U.S. in terms of revenue during the ... an average rate of 85% annually, and the company has ...
(Date:6/19/2013)... Kansas City will host its first Ciclovia event on Sept. 7, ... of Main Street in the midtown area will be restricted to ... The Main Street Corridor Development and BikeWalkKC are ... the ranks of dozens of cities across the US and Americas ... and active lifestyles. , “Ciclovia is the perfect event for the ...
(Date:6/19/2013)... Louis, MO (PRWEB) June 19, 2013 ... organization, partnered with ARAMARK Healthcare Technologies to help ... management plan with savings of more than 17 ... and maintenance service expenditures. , “Driving economies of ... top medical equipment management challenges facing multi-site providers,” ...
Breaking Medicine News(10 mins):Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2
... estimated 55,000 hospitalizations were prevented in U.S., researchers say ... rotavirus greatly reduces the risk of hospitalization for acute ... a leading cause of severe diarrhea and dehydration among ... a million deaths worldwide each year. The illness was ...
... ... from Pender County Schools and Framingham Public School District , ... Santa Clara, Calif. (PRWEB) May 14, ... announced today that it will host a Webcast entitled “Learning from your Peers: 802.11n ...
... decline sharply and risk of dying increases, study finds , ... clot-busting drug alteplase (tPA) within 4.5 hours of having a ... later, Scottish doctors report. , It has been known that ... study shows for the first time that there is significant ...
... ... Medical Marijuana Dispensaries in CA, Stock is Soaring.,California company announces, after ... medical marijuana dispensaries compliant with state and local laws. The stock ... For more complete coverage on the Business of Medical Marijuana, ...
... ... is pleased to announce the introduction of the Periowave™ HHL-1000 cordless, handheld ... Association, Booth # 430 & 432. Both products represent over 10 ... ), and over 20 years pre-clinical research at University College London, England. ...
... ... brings the Legal Hold Pro™ service into doeDiscovery™. Further expanding doeLegal,s capabilities across the ... leadership role to offer increased value to all eDiscovery clients. , ... (PRWEB) May 14, 2010 ...
Cached Medicine News:Health News:Rotavirus Vaccine Helps Kids Avoid Severe Gastro Illness 2Health News:Aerohive Networks Hosts Tech & Learning Customer Webcast Focusing on Easy to Deploy 802.11n Wi-Fi 2Health News:Early Treatment With Clot-Busting Drug Best After Stroke 2Health News:Early Treatment With Clot-Busting Drug Best After Stroke 3Health News:Cannabis Medical Solutions Announces Plan to Franchise Ownership of Medical Marijuana Dispensaries in California 2Health News:Cannabis Medical Solutions Announces Plan to Franchise Ownership of Medical Marijuana Dispensaries in California 3Health News:Periowave Dental Technologies Introduces Periowave™ HHL-1000 cordless, Handheld Laser at 2010 Ontario Dental Association Spring Meeting 2Health News:doeLegal and Zapproved Sign Alliance to Add Legal Hold Pro to Suite of Powerful Online Legal Solutions 2Health News:doeLegal and Zapproved Sign Alliance to Add Legal Hold Pro to Suite of Powerful Online Legal Solutions 3
... Chalam 15° Prism are designed ... are recommended for tractional retinal ... Rhegmatogenus retinal detachment. They can ... and other midperipheral laser applications. ...
... The High-Mag 1.5x ... internal limiting membrane peeling ... optic nerve neurotomy, sheathotomy ... traditional macular edema and ...
... The MiniQuad ACS allows visualization ... ora serrata, with essentially coaxial positioning of ... excellent for retinal detachment surgery, repairing giant ... vitreoretinopathy and for examining the peripheral retina ...
... With somewhat higher magnification and ... is best suited for detailed ... The Central Retinal is ideal ... in membrane peeling in proliferative ...
Medicine Products: